Skip to main content
SABS
NASDAQ Life Sciences

SAB Biotherapeutics Secures Key Manufacturing Agreement for Lead Diabetes Candidate SAB-142

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.69
Mkt Cap
$188.009M
52W Low
$1.53
52W High
$6.6
52W Position info
141% above low
Off High info
44% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

SABS has more than doubled off its 52-week low of $1.53.

Summary

SAB Biotherapeutics has signed a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for its lead Type 1 Diabetes candidate, SAB-142, committing to a minimum spend of $36 million over five years post-FDA approval.


Key Events · M&A and Partnerships · SABS

  • Material Manufacturing Agreement

    SAB Biotherapeutics entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for clinical and commercial manufacturing of its lead Type 1 Diabetes candidate, SAB-142.

  • Long-Term Financial Commitment

    The agreement has a term of five years from the date SAB-142 obtains FDA approval, with a minimum aggregate spend of $36 million during that period.

  • Supports Commercialization Pathway

    This agreement secures critical manufacturing capacity, following recent positive Phase 1 clinical data for SAB-142, and is a crucial step towards potential commercialization.


Analysis · SABS · Life Sciences

SAB Biotherapeutics has entered into a significant manufacturing agreement for its lead Type 1 Diabetes candidate, SAB-142. This Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. is a crucial step in de-risking the commercialization pathway for SAB-142, especially following the positive Phase 1 clinical data reported just two weeks prior. The commitment to a minimum aggregate spend of $36 million over five years post-FDA approval demonstrates a substantial investment in the product's future and secures a vital operational component for a biotech company. While the news was previously reported, this 8-K provides the official and detailed terms of the material agreement.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SABS was trading at $3.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188M. The 52-week trading range was $1.53 to $6.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SABS - Latest Insights

SABS
Nov 05, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.15
Real-time Price: $3.11 info
Change: -$0.040 (-1%) info
Market Cap: $280.176M info
SABS
Oct 13, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.98
Real-time Price: $3.11 info
Change: +$0.1326 (+4%) info
Market Cap: $280.176M info
SABS
Oct 13, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $3.11 info
Change: +$0.310 (+11%) info
Market Cap: $280.176M info
SABS
Aug 06, 2026, 7:56 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.85
Real-time Price: $3.11 info
Change: -$0.740 (-19%) info
Market Cap: $280.176M info
SABS
Jul 07, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.11
Real-time Price: $3.11 info
Change: -$0.9999 (-24%) info
Market Cap: $280.176M info